Management of Metastatic Skin Cancers in Organ Transplant Recipients

  • Steve Nicholson
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Metastatic skin cancer in the organ transplant population cannot be regarded as a common entity.

The experience of the Royal London Hospital (C.A. Harwood and C.M. Proby, personal communication) is useful to quantify the problem.


Clin Oncol Basal Cell Carcinoma mTOR Inhibitor Merkel Cell Carcinoma Liposomal Doxorubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Clerici M, et al. (1996) The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 88(7): 461–462.PubMedCrossRefGoogle Scholar
  2. 2.
    Hrouda D, et al. (1998) Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). BJU Int 82(4): 568–573.CrossRefGoogle Scholar
  3. 3.
    Maraveyas AD, et al. (1999) Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interkukin-2 in peripheral blood lymphocytes. Ann Oncol 10(7): 817–824.PubMedCrossRefGoogle Scholar
  4. Ryken T, et al. (2004) Evidence-based review of the surgical management of vertebral column metastatic disease. First retrieved 01/05/2004, 2004, from
  5. 5.
    Campistol JM, et al. (2007) Use of proliferation signal inhibitors in the management of post-transplant malignancies: clinical guidance. Nephrol Dial Transplant 22(suppl_1): i36–i41.PubMedCrossRefGoogle Scholar
  6. 6.
    De Graaf YGL, et al. (2004) Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 30(4p2): 656–661.PubMedCrossRefGoogle Scholar
  7. 7.
    Anonymous (2006) Improving Outcomes Guidance for People with Skin Tumours including Melanoma. London: National Institute for Health and Clinical Excellence.Google Scholar
  8. 8.
    West J, et al. (2005) Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial where both groups are managed according to a strict protocol. Qual Saf Health Care 14(3): 175–178.PubMedCrossRefGoogle Scholar
  9. 9.
    Martinez J-C, et al. (2004) Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg 30(4 pt 2): 679–686.PubMedCrossRefGoogle Scholar
  10. 10.
    Tessmer CS, et al. (2006) Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 82(12): 1792–1793.PubMedCrossRefGoogle Scholar
  11. 11.
    de Fijter JW (2007) Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 22(suppl_1): i23–i26.PubMedCrossRefGoogle Scholar
  12. 12.
    Lippman S, et al. (1992) 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235–241.PubMedCrossRefGoogle Scholar
  13. 13.
    Shin D, et al. (2002) Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2): 322–330.PubMedCrossRefGoogle Scholar
  14. 14.
    Stasko T, et al. (2004) Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 30(4 pt 2): 642–650.PubMedCrossRefGoogle Scholar
  15. 15.
    Khansur T, Kennedy A (1991) Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 67(8): 2030–2032.PubMedCrossRefGoogle Scholar
  16. 16.
    Sadek H, et al. (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66(8): 1692–1696.PubMedCrossRefGoogle Scholar
  17. 17.
    Guthrie TJ, et al. (1985) Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 55(8): 1629–1632.PubMedCrossRefGoogle Scholar
  18. 18.
    Shin D, et al. (1998) Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 25(2 Suppl 4): 40–44.PubMedGoogle Scholar
  19. 19.
    Cartei G, et al. (2000) Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23(2): 181–184.PubMedCrossRefGoogle Scholar
  20. 20.
    Pfeiffer P, et al. (1989) Chemotherapy in basal cell carcinoma. Complete remission of locally advanced basal cell carcinoma following treatment with chemotherapy containing cis-platinum. Ugeskr Laeg 151(34): 2150–2151.PubMedGoogle Scholar
  21. 21.
    Pfeiffer P, et al. (1990) Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 26(1): 73–77.PubMedGoogle Scholar
  22. 22.
    Neudorfer M, et al. (1993) Cisplatin and doxorubicin for invasive basal cell carcinoma of the eyelids. Ann Ophthalmol 25(1): 11–13.PubMedGoogle Scholar
  23. 23.
    Chimenti S, et al. (1995) Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 190(3): 214–217.PubMedCrossRefGoogle Scholar
  24. 24.
    Campistol JM, et al. (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17(2): 581–589.PubMedCrossRefGoogle Scholar
  25. 25.
    Zmonarski S, et al. (2005) Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37(2): 964–966.PubMedCrossRefGoogle Scholar
  26. 26.
    Campistol JM, Schena FP (2007) Kaposi’s sarcoma in renal transplant recipients: the impact of proliferation signal inhibitors. Nephrol Dial Transplant 22(suppl_1): i17–i22.PubMedCrossRefGoogle Scholar
  27. 27.
    Walmsley S, et al. (1999) Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 22(3): 235–246.PubMedGoogle Scholar
  28. 28.
    Bodsworth N, et al. (2001) Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol 2(2): 77–87.PubMedCrossRefGoogle Scholar
  29. 29.
    Hauschild A, Petres-Dunsche C (1992) Intralesional treatment of classical Kaposi sarcoma with interferon-alpha. Hautarzt 43(12): 789–791.PubMedGoogle Scholar
  30. 30.
    Flaitz C, et al. (1995) Role of intralesional vinblastine administration in treatment of intraoral Kaposi’s sarcoma in AIDS. Eur J Cancer B Oral Oncol 31B(4): 280–285.PubMedCrossRefGoogle Scholar
  31. 31.
    Odom R, Goette D (1978) Treatment of cutaneous Kaposi’s sarcoma with intralesional vincristine. Arch Dermatol 114(11): 1693–1694.PubMedCrossRefGoogle Scholar
  32. 32.
    Poignonec S, et al. (1995) Intralesional bleomycin for acquired immunodeficiency syndrome-associated cutaneous Kaposi’s sarcoma. Arch Dermatol 131(2): 228.PubMedCrossRefGoogle Scholar
  33. 33.
    Fife K, et al. (1998) Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titre. Int J STD AIDS 9:751–755.PubMedCrossRefGoogle Scholar
  34. 34.
    Little RF, et al. (2000) Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 18(13): 2593–2602.PubMedGoogle Scholar
  35. 35.
    Northfelt DW, et al. (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7): 2445–2451.PubMedGoogle Scholar
  36. 36.
    Stewart S, et al. (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16(2): 683–691.PubMedGoogle Scholar
  37. 37.
    Laubenstein L, et al. (1984) Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2(10): 1115–1120.PubMedGoogle Scholar
  38. 38.
    Brambilla L, et al. (1994) Mediterranean Kaposi’s sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer 74(10): 2873–2878.PubMedCrossRefGoogle Scholar
  39. 39.
    Lim S, et al. (2005) Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 103(2): 417–421.PubMedCrossRefGoogle Scholar
  40. 40.
    Guba M, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2): 128–135.PubMedCrossRefGoogle Scholar
  41. 41.
    Margolin K, et al. (2005) CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104(5): 1045–1048.PubMedCrossRefGoogle Scholar
  42. 42.
    Rao R, et al. (2006) Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol 24(18S): 8043.Google Scholar
  43. 43.
    Romano MF, et al. (2004) Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 40(18): 2829–2836.PubMedCrossRefGoogle Scholar
  44. 44.
    Sampson J, et al. (1998) Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Fife K, et al. (2004). Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7): 1293–1300.PubMedCrossRefGoogle Scholar
  46. 46.
    Agrawal S, et al. (1999) Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 6(4): 336–344.PubMedCrossRefGoogle Scholar
  47. 47.
    Gutman H, et al. (2001) Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25(6): 750–758.PubMedCrossRefGoogle Scholar
  48. 48.
    Wood T, et al. (2001) Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 8(8): 658–662.PubMedCrossRefGoogle Scholar
  49. 49.
    Ollila D, et al. (1998) Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma [see comment]. J Surg Oncol 69(4): 206–211.PubMedCrossRefGoogle Scholar
  50. 50.
    Morris SL, et al. (2004) A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 91(5): 829–833.PubMedGoogle Scholar
  51. 51.
    Gaudy-Marqueste C, et al. (2006) Gamma-knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 65(3): 809–816.PubMedGoogle Scholar
  52. 52.
    Samlowski WE, et al. (2007) Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109(9): 1855–1862.PubMedCrossRefGoogle Scholar
  53. 53.
    Middleton M, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1): 158–166.PubMedGoogle Scholar
  54. 54.
    Kiebert G, et al. (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21(6): 821–829.PubMedCrossRefGoogle Scholar
  55. 55.
    Agarwala S, et al. (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22:2101–2107.PubMedCrossRefGoogle Scholar
  56. 56.
    Legha S (1997) The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 24(Suppl 4): S24–S31.PubMedGoogle Scholar
  57. 57.
    Suranyi M, et al. (1998) Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 66(5): 655–661.PubMedCrossRefGoogle Scholar
  58. 58.
    Phan G, et al. (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19(15 3477–3482).PubMedGoogle Scholar
  59. 59.
    Ridolfi R, et al. (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20(6): 1600–1607.PubMedCrossRefGoogle Scholar
  60. 60.
    Bajetta E, et al. (2006). Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17(4): 571–577.PubMedCrossRefGoogle Scholar
  61. 61.
    Maker AV, et al. (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29(4): 455–463.PubMedCrossRefGoogle Scholar
  62. 62.
    Eisen T, et al. (2007) An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol 25(18S): 8529.Google Scholar
  63. 63.
    Eiling S, et al. (2002) Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 147:150–153.PubMedCrossRefGoogle Scholar
  64. 64.
    Fata F, et al. (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86(10): 2034–2037.PubMedCrossRefGoogle Scholar
  65. 65.
    Fiore M, et al. (2005) Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 23(30): 7669–7675.PubMedCrossRefGoogle Scholar
  66. 66.
    Sjoblom T, et al. (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61(15): 5778–5783.PubMedGoogle Scholar
  67. 67.
    Rubin BP, et al. (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20(17): 3586–3591.PubMedCrossRefGoogle Scholar
  68. 68.
    Plunkett T, et al. (2001) Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol 12(3): 411–414.PubMedCrossRefGoogle Scholar
  69. 69.
    Huet P, et al. (1996) Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol 35(5 pt 2): 860–864.PubMedCrossRefGoogle Scholar
  70. 70.
    Gonzalez-Lopez M, et al. (2003) Metastatic eccrine porocarcinoma: a 5.6-year follow-up study of a patient treated with a combined therapeutic protocol. Dermatol Surg 29(12): 1227–1232.PubMedCrossRefGoogle Scholar
  71. 71.
    de Bree E, et al. (2004) Treatment of advanced malignant eccrine poroma with locoregional chemotherapy. Br J Dermatol 152:1051–1055.CrossRefGoogle Scholar
  72. 72.
    Gutermuth J, et al. (2004) Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Vener 18(4): 477–479.CrossRefGoogle Scholar
  73. 73.
    Roach M III (1983) A malignant eccrine poroma responds to isotretinoin (13-cis-retinoic acid). Ann Intern Med 99(4): 486–488.PubMedGoogle Scholar
  74. 74.
    Morgan D, et al. (1987) Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer. Eur J Cancer Clin Oncol 23(6): 619–621.PubMedCrossRefGoogle Scholar
  75. 75.
    Tai P, et al. (2000) Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18(12): 2493–2499.PubMedGoogle Scholar
  76. 76.
    Voog E, et al. (1999) Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85(12): 2589–2595.PubMedCrossRefGoogle Scholar
  77. 77.
    Poulsen M, et al. (2003) High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans Tasman Radiation Oncology Group Study – TROG 96:07. J Clin Oncol 21(23): 4371–4376.PubMedCrossRefGoogle Scholar
  78. 78.
    Robson R, et al. (2003) Risk of PTLD and other malignancies in renal transplant patients treated with MMF: a prospective observational cohort study. Am J Transplant 3(s5): 187.Google Scholar
  79. 79.
    Pascual J (2007) Post-transplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 22(suppl_1): i27–i35.PubMedCrossRefGoogle Scholar
  80. 80.
    Rupoli S, et al. (1999) Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica 84(9): 809–813.PubMedGoogle Scholar
  81. 81.
    Chiarion-Sileni V, et al. (2002) Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 95(3): 569–575.PubMedCrossRefGoogle Scholar
  82. 82.
    Thomsen K, et al. (1989) Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Dermatol Venereol 69(6): 536–538.Google Scholar
  83. 83.
    Stadler R, et al. (1998) Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92(10): 3578–3581.PubMedGoogle Scholar
  84. 84.
    Duvic M, et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II–III trial results. J Clin Oncol 19:2456–2471.PubMedGoogle Scholar
  85. 85.
    Tsai DE, et al. (2005) Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. Am J Transplant 5(8): 2070–2073.PubMedCrossRefGoogle Scholar
  86. 86.
    Garber K (2001) Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst 93(20): 1519.PubMedCrossRefGoogle Scholar
  87. 87.
    Euvrard S, et al. (2004) Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 30(4 pt 2): 628–633.PubMedCrossRefGoogle Scholar
  88. 88.
    Witzig TE, et al. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23(23): 5347–5356.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Steve Nicholson
    • 1
  1. 1.University Hospitals of LeicesterLeicesterUK

Personalised recommendations